Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression

This publication has 55 references indexed in Scilit:

• DUSP1 Expression Induced by HDAC1 Inhibition Mediates Gefitinib Sensitivity in Non–Small Cell Lung Cancers
  Clinical Cancer Research, 2015
• Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
  Journal of Translational Medicine, 2013
• Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer
  Oncotarget, 2013
• Epigenetics
  Epigenetics, 2012
• HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance
  Cancer Letters, 2011
• Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis
  Molecular Cancer Therapeutics, 2009
• HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors
  Clinical Cancer Research, 2009
• Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis
  Science Signaling, 2009
• Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN-α in Head and Neck Cancer Cells In vitro and In vivo
  Clinical Cancer Research, 2006
• New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
  JNCI: Journal of the National Cancer Institute, 1990